Combined Targeted Therapy of Herceptin and Perjeta for HER2-Positive Breast Cancer, a Systemic Review
Objective: To review current literature regarding the survival rates of women with HER2-positive breast cancer using the targeted treatment therapy of Herceptin and Perjeta along with docetaxel (chemotherapy) versus Herceptin and docetaxel alone. Methods: Literature was gathered through PubMed and Google Scholar that assessed the effectiveness of Herceptin and Perjeta treatment on HER2-positve breast cancer. The treatment consisted of injections of Herceptin and Perjeta along with docetaxel. Results: The literature indicates that overall, a treatment therapy of Herceptin and Perjeta along with docetaxel resulted in greater survival rates among HER2-positive breast cancer patients than with Herceptin and docetaxel alone. Conclusions: Targeted drug therapy of Herceptin and Perjeta along with docetaxel shows promising improvements in survival rates for women with HER2-positive breast cancer. The treatments studied in this review should be further researched to determine which lead to the best outcomes.